A
ABVC BioPharma, Inc. (ABVC)
NCM – Real Time Price. Currency in USD
1.05
+0.03 (2.94%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.05
+0.03 (2.94%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 0.41 | 6.05 | 4.0 | |
| Quick ratio | 0.41 | 5.63 | 4.0 | |
| Debt to Equity | 0.32 | 0.30 | 7.0 | |
| Debt to Assets | 0.17 | 1.04 | 8.0 | |
| Interest coverage | -67.55 | -16.91 | 1.0 | |
| Weighted average score | 4.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 970K | 152K | 510K | N/A | N/A |
| Gross Profit | 660K | -530K | 308K | -505K | -505K |
| Operating Income | -15M | -7M | -5M | -7M | -7M |
| Net Income | -16M | -8M | -5M | -8M | -8M |
| EBITDA | -15M | -6M | -5M | -7M | -7M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | N/A | 1.0 |
| Next quarter | N/A | N/A | 1.0 |
| Current year | N/A | N/A | 1.0 |
| Next year | 745.53 | 128.26 | 10 |
| Weighted average score | 3.3 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -35.46 | N/A | 38.49 | 5.5 |
| Y/Y | -99.99 | -1306.68 | N/A | -139.77 | 1.0 |
| 3y average | 16.68 | 9.45 | N/A | 12.46 | 5.8 |
| 5y average | 39.26 | -6.13 | 16.44 | 2.07 | 5.8 |
| Weighted average score | 4.5 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Total debt $3.6M significantly exceeds cash reserves ($1.3M), raising financial stability concerns
Total current liabilities $6.2M surpass Total current assets $2.5M, signaling liquidity issues
Debt-to-equity ratio (0.3) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-67.6x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$593.4K limits the company's ability to reinvest or pay down debt